Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab

Biologic Response of Colorectal Cancer Xenograft Tumors to Sequential Treatment with Panitumumab and Bevacizumab

Recent studies in RAS wild-type (WT) metastatic colorectal cancer (mCRC) suggest that the survival benefits of therapy using anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) antibodies combined with chemotherapy are maximized when the anti-EGF...

Full description

Bibliographic Details
Main Authors:	Hiroya Taniguchi, Yuji Baba, Yoji Sagiya, Masamitsu Gotou, Kazuhide Nakamura, Hiroshi Sawada, Kazunori Yamanaka, Yukiko Sakakibara, Ikuo Mori, Yukiko Hikichi, Junpei Soeda, Hideo Baba
Format:	Article
Language:	English
Published:	Elsevier 2018-07-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558618301714

Similar Items

Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G
by: Hiroya Taniguchi, et al.
Published: (2020-06-01)

Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models
by: Michael J. Boedigheimer, et al.
Published: (2013-02-01)

Co-Treatment with Panitumumab and Trastuzumab Augments Response to the MEK Inhibitor Trametinib in a Patient-Derived Xenograft Model of Pancreatic Cancer
by: James M. Lindberg, et al.
Published: (2014-07-01)

Metastatic colorectal cancer: treatment with panitumumab
by: Antonio Silvinato, et al.

Antitumor Effect of Bevacizumab in a Xenograft Model of Canine Hemangiopericytoma
by: Masaki Michishita, et al.
Published: (2013-01-01)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
by: Masaaki Miyo, et al.
Published: (2020-07-01)

Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab′)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab′)2 – implications for a PET theranostic strategy
by: Anthony Ku, et al.
Published: (2021-08-01)

Treatment of metastatic colorectal cancer: focus on panitumumab
by: Tay RY, et al.
Published: (2015-06-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-02-01)

Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
by: Miriam López-Gómez, et al.
Published: (2012-01-01)

HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
by: Tapan K Nayak, et al.
Published: (2011-03-01)

Patient considerations in metastatic colorectal cancer – role of panitumumab
by: Rogers JE
Published: (2017-04-01)

Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu
by: Sadaf Aghevlian, et al.
Published: (2020-11-01)

Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer
by: Kozue Matsuishi, et al.
Published: (2020-06-01)

RESULTS OF PANITUMUMAB ADDITION TO CONVERSION THERAPY FOR COLORECTAL CANCER LIVER METASTASES
by: M. I. Sekacheva, et al.
Published: (2015-02-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors
by: Jesús García-Foncillas, et al.
Published: (2019-09-01)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
by: Adriana Camargo Carvalho, et al.
Published: (2017-01-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Panitumumab-induced acneiform rash in a patient with metastatic colon adenocarcinoma
by: Paulo Ricardo Saquete Martins-Filho, et al.
Published: (2013-01-01)

Papulopustular lesions of the face caused by panitumumab: case report and literature review
by: Ravasco Jonathan, et al.
Published: (2018-06-01)

Treatment of Rectal Cancer-Induced Disseminated Carcinomatosis of the Bone Marrow with FOLFOX plus Cetuximab and Panitumumab
by: Takehito Ehara, et al.
Published: (2020-02-01)

Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET.
by: Albert J Chang, et al.
Published: (2013-01-01)

Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model
by: Véronique Mathieu, et al.
Published: (2008-12-01)

The Combination of Nab-Paclitaxel and Bevacizumab Therapy Synergistically Improves Tumor Response in Xenograft Breast Cancer Models
by: Volk, Lisa Danielle
Published: (2008)

REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Letter]
by: Hendrikx JJMA, et al.
Published: (2020-10-01)

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Functional Dissection of the Epidermal Growth Factor Receptor Epitopes Targeted by Panitumumab and Cetuximab
by: Mareike Voigt, et al.
Published: (2012-11-01)

Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer
by: Howard Burris, et al.
Published: (2011-01-01)

Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer
by: Giampietro Gasparini, et al.
Published: (2014-09-01)

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab
by: George P Kim, et al.
Published: (2008-06-01)

Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
by: Shigemasa Takamizawa, et al.
Published: (2021-02-01)

Panitumumab v terapii metastaticheskogokolorektal'nogo raka: dannye klinicheskikhissledovaniy, problema kozhnoy toksichnosti
by: E V Artamonova
Published: (2010-09-01)

Is Bodyweight-Based Dosing Truly Better Than Flat Dosing for Panitumumab? [Response to Letter]
by: Liao MZ, et al.
Published: (2020-12-01)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance.
by: E Allen Sickmier, et al.
Published: (2016-01-01)

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab
by: Yifan Xu, et al.
Published: (2018-11-01)

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
by: Kerry J Williams, et al.
Published: (2009-06-01)

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
by: Daanish Hoda, et al.
Published: (2008-09-01)

Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma
by: Kubota-Taniai M, et al.
Published: (2011-07-01)